GLIOBLASTOMA MOUSE MODEL DEVELOPMENT & THE FUTURE OF GBM RESEARCH

Orthotopic Models, Focal Radiation and More For Your Preclinical Studies

In GBM research, a clinically relevant glioblastoma mouse model combined with advanced translational oncology approaches enable accurate assessment of drug delivery to the brain. Specialized surgical skills and imaging allow for the development and assessment of orthotopic models, which have been shown to retain the same genomic, histological, epigenetic, and treatment response characteristics as parental tumors and identify the gene signatures and pathways signatures associated with the clinical aggressiveness of GBMs.1,2 Additionally, focal radiation affords researchers the ability to develop more disease-relevant patient-derived xenograft (PDX) models and to more closely mimic clinical scenarios.

Advance Your GBM Research

Learn more about advancing your GBM research with focal radiation for in vitro and in vivo models, as well as our well-characterized intracranial orthotopic models / 3D cancer models, with patient history, treatment history; survival rates, growth kinetics, growth sensitivity and stem cell marker data.

DOWNLOAD GBM DATA PACK SUMMARY

STEREOTACTIC IMPLANTATION & CONVECTION ENHANCED DELIVERY

Specialized intracranial microsurgery expertise and instrumentation results in speed, precision and a > 90% GBM tumor take rate.3 Certis skilled microsurgeons use extreme care to promote homeostasis within the brain, using stereotactic implantation to optimize placement of cells in brain tissue, and convection enhanced delivery to optimize placement of tested compounds in brain tissue. A minimally invasive, single surgery allows for testing of cellular therapeutics, CAR-T’s, small molecule inhibitors and chemotherapies and is associated with low (<5%) perioperative mortality.3

Add Speed, Flexibility and Precision to Your GBM Research

Advanced imaging and analytical techniques precisely measure therapeutic response, providing visual proof when a drug formulation successfully crosses the BBB and regresses GBM tumors. Our high-resolution technologies are non-invasive, allowing animals to be evaluated with little disruption. A highly sensitive optical fluorescence and bioluminescence imaging system (using one cell line) is useful in analyzing the effects of a glioblastoma immunotherapy or combinatory chemotherapeutic (or measuring how much of the compound(s) actually crosses the BBB) while murine-scale MRIs deliver objective, precise tumor volume measurements (TVMs) and can monitor GBM recurrence.

LEARN MORE

Validation of Orthotopic vs. Subcutaneous In Vivo Tumor Growth Model in Mice. A comparison of variable tumor growth in mice without any treatment using patient-derived xenograft 3D cancer models / GBM tumorspheroids from primary or recurrent tumors excised from the same patient.4

Certis Glioblastoma 3D Cancer Models

Download Data Summary


References

1 Patrizii M, Bartucci M, Pine SR, Sabaawy HE. Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol. 2018;8:23
2 Joo KM, Kim J, Jin J, et al. Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ. Cell Rep. 2013;3(1):260-273.]
3 Baumann BC, Dorsey JF, Benci JL et al. Stereotactic Intracranial Implantation and In Vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme. J Vis Exp. 2012;(67):4089.
4 Rajan RG, Fernandez-Vega V, Sperry J, Nakashima J, Do LH, Andrews W, Boca S, Islam R, Chowdhary SA, Seldin J, et al. In Vitro and In Vivo Drug-Response Profiling Using Patient-Derived High-Grade Glioma. Cancers. 2023; 15(13):3289.